Abstract

Modified FOLFIRINOX is the standard of care for advanced pancreatic cancer and has expanded application in biliary tract and colorectal cancers. Despite its efficacy, real world data suggests nearly 75% of patients are unable to maintain dose intensity leading to reduction in efficacy and survival. We proposed to evaluate the dose intensity (DI) and toxicity of patients planned for mFOLFIRINOX.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call